11/12/2021 7:03:17 AM
Leap Therapeutics Q3 Loss Per Share $0.14 Vs Loss $0.09 Last Year
9/22/2021 8:35:05 AM
Leap Therapeutics Announces Pricing Of $90 Mln Of Common Stock And Pre-Funded Warrants
9/16/2021 2:59:08 AM
Leap: DKN-01 Plus Tislelizumab & Chemotherapy Show Activity In Patients With Gastric Or Gastroesophageal Junction Cancer
9/13/2021 6:01:33 AM
Leap Therapeutics To Present New Data From DisTinGuish Study Of DKN-01 Plus Tislelizumab At ESMO 2021 Congress
8/13/2021 7:07:04 AM
Leap Therapeutics Q2 Loss Per Share $0.12, Flat With Prior Year
5/14/2021 8:09:37 AM
Leap Therapeutics Q1 Loss Per Share $0.12 Vs Loss Per Share $0.55 Year Ago
5/12/2021 8:07:52 AM
Leap Therapeutics And Flagship Biosciences Develops An Image Analysis RNAscope Assay
4/12/2021 8:20:19 AM
Flagship Biosciences, Leap Therapeutics Announce Deal For Tumor Expression Assay Utilizing RNAscope And Image Analysis
3/22/2021 6:02:26 AM
Leap Therapeutics Presents DKN-01 Clinical Data At Society Of Gynecologic Oncology 2021 Meeting On Women's Cancer
3/12/2021 7:02:02 AM
Leap Therapeutics Q4 Loss Per Share $0.09 Vs Loss $0.33 Last Year
12/22/2020 10:25:10 AM
Leap Therapeutics Reports Publication Of DKN-01 Mechanism Of Action Data In Molecular Cancer Research